Market Cap
$3.3M
REVB
REVELATION BIOSCIENCES, INC.
$0.7636 ▼ -4.67%
Prev close $0.8010Market cap$3.3M
12-mo target$17.75 (+2224.5%)
Biotech & Drug Discovery
Snapshot
The big-picture read on REVB right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
8 funds
Inst. Value
$72.2K
Inst. Activity
0 buys / 1 sells
SEC Reports
2
Price chart 30d -24.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 19, 2026 SEC
Revelation Biosciences granted restricted stock awards to CEO James Rolke (208,076 shares) and CFO Chester Zygmont (208,
8-K — Impact 3/10
Aug 17, 2026 Insider
Rolke James was granted 208,076 shares
Chief Executive Officer
Aug 17, 2026 Insider
ROPER JESS was granted 32,011 shares
Director
Aug 17, 2026 Insider
Chawla Lakhmir S was granted 32,011 shares
Director
Aug 6, 2026 earnings_calendar
REVB Q2 2026 Earnings Scheduled — 2026-08-06
Jun 30, 2026 Inst.
Jun 25, 2026 SEC GEODE CAPITAL MANAGEMENT, LLC — TRIM
17,192 shares ($17.7K)
Revelation Biosciences filed an 8-K covering: (1) amended CEO/CFO employment agreements with enhanced change-in-control
8-K — Impact 4/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Aug 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jul 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Price targets
Where 2 covering analysts think REVB trades over the next 12 months.
$17.75 +2224.5% upside Strong Buy
Current$0.7636 Low$16.00 Median$17.75 High$19.50 2 analysts
$16.00$19.50
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
2 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 2 neutral · avg impact 3.5/10.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 6, 2026
earnings_calendar
REVB Q2 2026 Earnings Scheduled — 2026-08-06
May 6, 2026
earnings_calendar
REVB Q1 2026 Earnings Scheduled — 2026-05-06
Mar 4, 2026
earnings_calendar
REVB Q4 2025 Earnings After Market Close — 2026-03-04
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.88 | $-0.94–$-0.82 | 87.6% | -9.3% | — | $0.0B | 2 |
| Next Q | $-0.85 | $-0.94–$-0.77 | 48.2% | -8.9% | — | $0.0B | 2 |
| Current FY | $-5.18 | $-5.20–$-5.17 | 78.3% | -3.8% | 1↑ 0↓ | $0.0B | 2 |
| Next FY | $-2.89 | $-3.42–$-2.36 | 44.3% | -4.1% | 1↑ 0↓ | $0.0B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.880 | — |
| 7d ago | $-0.805 | -0.075 |
| 30d ago | $-0.805 | -0.075 |
| 60d ago | $-0.805 | -0.075 |
| 90d ago | $-0.805 | -0.075 |
Institutional ownership
Which big funds own REVB (from quarterly 13F filings) and who is adding or trimming.
8 institutional holders with $72.2K total value (86,800 shares) as of 2026-Q2. Top holders: FMR, CITADEL, GEODE. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 0 | $0.00 | 0.0% | — |
| CITADEL ADVISORS LLC | 38,579 | $39.7K | 55.1% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 17,192 | $17.7K | 24.5% | TRIM -60.2% |
| VANGUARD FIDUCIARY TRUST CO | 13,127 | $13.5K | 18.7% | — |
| ROYAL BANK OF CANADA | 747 | $1.0K | 1.4% | — |
| BARCLAYS PLC | 168 | $173.00 | 0.2% | — |
| HRT FINANCIAL LP | 16,978 | $17.00 | 0.0% | — |
| BNP Paribas Asset Management Holding S.A. | 9 | $9.00 | 0.0% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | 43,195 | 17,192 | -60.2% | $17.7K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
5 insiders, 13 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Rolke James | Chief Executive Officer | AWARD | 208,076 | — | — |
| Aug 17, 2026 | ROPER JESS | Director | AWARD | 32,011 | — | — |
| Aug 17, 2026 | Chawla Lakhmir S | Director | AWARD | 32,011 | — | — |
| Aug 17, 2026 | Zygmont Chester Stanley III | Chief Financial Officer | AWARD | 208,073 | — | — |
| Aug 17, 2026 | Zygmont Chester Stanley III | Chief Financial Officer | GIFT | 208,073 | — | — |
| Aug 17, 2026 | CARVER JENNIFER | Director | AWARD | 32,011 | — | — |
| Apr 30, 2026 | Zygmont Chester Stanley III | Chief Financial Officer | TAX W/H | 13,285 | $1.10 | $14.6K |
| Apr 30, 2026 | Rolke James | Chief Executive Officer | TAX W/H | 10,115 | $1.13 | $11.4K |
| Feb 4, 2026 | Zygmont Chester Stanley III | Chief Financial Officer | TAX W/H | 13,100 | $1.65 | $21.6K |
| Feb 3, 2026 | ROPER JESS | Director | TAX W/H | 1,591 | $1.85 | $2.9K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for REVB.
Shares short
256
Settlement Sep 15, 2026
Change vs prior
-56.0%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈0.0%
Estimate — not % of float
All REVB filing & press-release reports (2)
- 8-K reportAug 19, 2026
- 8-K reportJun 25, 2026